AZN: H1 2018 Results
AstraZeneca PLC
26 July 2018 07:00 BST
H1 2018 Results
Strong performances from new medicines and Emerging Markets underpin the return to growth in 2018
Over the first half, the strong sales growth from new medicines (+75%, +69% at CER1) and the continued strength of the Emerging Markets business (+14%, +10% at CER) were offset by the impact from the loss of Crestor exclusivity in Europe and Japan. In line with expectations, an improved performance is anticipated in the second half, notably Product Sales, where guidance is reiterated for a low single-digit percentage increase over the full year at CER. Important news flow from the pipeline is expected to continue beyond the rest of the year.
Financial Highlights
| H1 2018 | Q2 2018 | |||||
| $m | % change | $m | % change | |||
| Actual | CER | Actual | CER | |||
| Total Revenue | 10,333 | (1) | (5) | 5,155 | 2 | (1) |
| Product Sales | 10,015 | 2 | (2) | 5,030 | 2 | (1) |
| Externalisation Revenue | 318 | (53) | (54) | 125 | 14 | 14 |
| Reported Operating Profit2 | 1,459 | (21) | (20) | 763 | (17) | (20) |
| Core Operating Profit3 | 2,161 | (33) | (34) | 1,265 | (18) | (22) |
| Reported Earnings Per Share (EPS) | $0.54 | (32) | (34) | $0.27 | (27) | (38) |
| Core EPS | $1.17 | (37) | (39) | $0.69 | (21) | (26) |
Click on, or paste the following link into your web browser, to view the associated PDF document.
http://www.rns-pdf.londonstockexchange.com/rns/7998V_1-2018-7-25.pdf
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.